Clinical Trials Logo

HDL clinical trials

View clinical trials related to HDL.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05641584 Completed - Inflammation Clinical Trials

Is Monocyte/HDL Ratio a Predictor of Mortality in Aortic Valve Surgery

Start date: May 10, 2022
Phase:
Study type: Observational

In this study, the investigators aimed to determine whether the preoperative Monocyte/HDL ratio would be a predictor of postoperative mortality and morbidity in patients who underwent aortic valve replacement due to aortic stenosis.

NCT ID: NCT04529174 Completed - HDL Clinical Trials

Oral Nutritional Supplement Effect on HDL Function

Start date: August 18, 2020
Phase: N/A
Study type: Interventional

Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL particle size and HDL particle number (HDL-P)

NCT ID: NCT04330209 Completed - Weight Loss Clinical Trials

Comparing a Low-GI Nutrigenetic and Ketogenic Diet for Weight Loss With 18 Month Follow-up

LOWGI_GENE
Start date: January 1, 2014
Phase:
Study type: Observational

The investigators followed a convenience sample of 114 overweight and obese subjects from a weight loss clinic who followed a 24-week dietary intervention. The subjects self-selected whether to follow a standardized ketogenic diet (n=53), or a personalised low-glycemic index (GI) diet utilising information from 28 single nucleotide polymorphisms (n=61). After the 24-week study period, the subjects were monitored for an additional 18 months.

NCT ID: NCT03205254 Completed - Inflammation Clinical Trials

Effects of Short-term Diet on HDL Composition and Function

Start date: March 28, 2016
Phase: N/A
Study type: Interventional

The primary objective of this study is to generate preliminary data on the effects of a short-term diet of either fast food or Mediterranean type diet on HDL and microbiota composition and function in healthy subjects, which includes both normal weight and overweight/obese subjects.

NCT ID: NCT01284582 Completed - Drug Safety Clinical Trials

Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)

Start date: May 2011
Phase: Phase 1
Study type: Interventional

Phase 1 Study :Safety, Immunogenicity and Dose response of ATH03, a new vaccine against the cholesterol ester transfer protein (CETP), in healthy male subjects with high density lipoprotein cholesterol (HDLc) blood concentrations equal or below 80 mg/dl.